Last reviewed · How we verify
Cryotherapy + Tirbanibulin
Cryotherapy physically destroys actinic keratosis lesions through freezing, while tirbanibulin is a non-steroidal topical agent that induces keratinocyte apoptosis to treat actinic keratosis.
Cryotherapy physically destroys actinic keratosis lesions through freezing, while tirbanibulin is a non-steroidal topical agent that induces keratinocyte apoptosis to treat actinic keratosis. Used for Actinic keratosis.
At a glance
| Generic name | Cryotherapy + Tirbanibulin |
|---|---|
| Also known as | Cryotherapy + placebo |
| Sponsor | University Hospital, Lille |
| Drug class | Combination therapy: cryotherapy + Src kinase inhibitor |
| Target | Src kinase (tirbanibulin component) |
| Modality | Small molecule |
| Therapeutic area | Dermatology/Oncology |
| Phase | Phase 3 |
Mechanism of action
This combination approach uses cryotherapy (liquid nitrogen freezing) to ablate visible actinic keratosis lesions, followed by tirbanibulin application to target remaining or subclinical lesions. Tirbanibulin is a Src kinase inhibitor that promotes apoptosis in dysplastic keratinocytes. The dual mechanism addresses both clinical and subclinical disease.
Approved indications
- Actinic keratosis
Common side effects
- Local skin irritation (erythema, scaling)
- Pain or discomfort at treatment site
- Cryotherapy-induced blistering or crusting
- Pruritus
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cryotherapy + Tirbanibulin CI brief — competitive landscape report
- Cryotherapy + Tirbanibulin updates RSS · CI watch RSS
- University Hospital, Lille portfolio CI